SCHEMBL24997465

SCHEMBL24997465

FC(F)(F)c1cnc2nccn2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.49
GRM5 P41594 1/20 0.40
NAMPT P43490 6/20 0.39
CYP1A2 P05177 1/20 0.35
METAP2 P50579 1/20 0.35
MCHR1 Q99705 1/20 0.35
OGA O60502 1/20 0.35
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
IDO1 P14902 1/20 0.31
TDO2 P48775 1/20 0.31
AGBL2 Q5U5Z8 1/20 0.31
PKM P14618 1/20 0.31
KMT2A Q03164 1/20 0.31
MERTK Q12866 1/20 0.31
NOS3 P29474 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL255066 0.82 DYRK1A (0.47) DYRK1ANAMPTKDM4EALDH1A1KMT2A
SCHEMBL24087053 0.75 DYRK1A (0.52) DYRK1ANAMPTKDM4EALDH1A1
SCHEMBL18306988 0.71 DYRK1A (0.52) DYRK1ANAMPTKDM4EALDH1A1
SCHEMBL9611694 0.71 DYRK1A (0.52) DYRK1ANAMPTKDM4ENPC1ALDH1A1
SCHEMBL18371401 0.71 DYRK1A (0.52) DYRK1ANAMPTKDM4ENPC1ALDH1A1
SCHEMBL484140 0.71 DYRK1A (0.52) DYRK1ANAMPTKDM4ENPC1ALDH1A1
SCHEMBL19053825 0.71 DYRK1A (0.52) DYRK1ANAMPTKDM4EALDH1A1RAB9A
SCHEMBL3034110 0.71 MCHR1 (0.56) DYRK1AGRM5NAMPTCYP1A2METAP2
SCHEMBL15639366 0.70 MAOB (0.44) DYRK1AGRM5NAMPTKDM4EALDH1A1
Bromide SCHEMBL4315989 0.69 DYRK1A (0.50) DYRK1ANAMPTKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230037538-A1 ANTI-ALS COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230037538-A1 ANTI-ALS COMPOUNDS TARDBP, GRN, NLN DYRK1A 4795/4885GRM5 643/4885NAMPT 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.